Eqis Capital Management Inc. lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 23.8% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 66,127 shares of the biopharmaceutical company’s stock after selling 20,665 shares during the period. Eqis Capital Management Inc.’s holdings in Gilead Sciences were worth $4,468,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Cooper Financial Group raised its holdings in shares of Gilead Sciences by 4.3% in the 2nd quarter. Cooper Financial Group now owns 3,604 shares of the biopharmaceutical company’s stock valued at $243,000 after purchasing an additional 149 shares in the last quarter. Lenox Wealth Management Inc. raised its stake in Gilead Sciences by 1.8% during the 1st quarter. Lenox Wealth Management Inc. now owns 9,059 shares of the biopharmaceutical company’s stock worth $589,000 after acquiring an additional 156 shares in the last quarter. Creative Financial Designs Inc. ADV raised its stake in Gilead Sciences by 55.9% during the 1st quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 165 shares in the last quarter. Rathbone Brothers plc raised its stake in Gilead Sciences by 3.1% during the 1st quarter. Rathbone Brothers plc now owns 5,547 shares of the biopharmaceutical company’s stock worth $361,000 after acquiring an additional 167 shares in the last quarter. Finally, Unison Advisors LLC raised its stake in Gilead Sciences by 1.0% during the 2nd quarter. Unison Advisors LLC now owns 17,996 shares of the biopharmaceutical company’s stock worth $1,216,000 after acquiring an additional 170 shares in the last quarter. 78.85% of the stock is owned by hedge funds and other institutional investors.

Several brokerages recently commented on GILD. Credit Suisse Group began coverage on shares of Regeneron Pharmaceuticals in a research note on Monday, May 20th. They set a “neutral” rating and a $336.00 price target on the stock. Oppenheimer set a $85.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Friday, July 12th. Cantor Fitzgerald set a $88.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Monday, July 15th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Gilead Sciences in a research note on Tuesday, July 2nd. Finally, Morgan Stanley set a $70.00 price target on shares of Edison International and gave the stock a “hold” rating in a research note on Monday, July 15th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $81.56.

In related news, Director John Francis Cogan sold 2,868 shares of the business’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $64.89, for a total transaction of $186,104.52. Following the sale, the director now owns 57,728 shares of the company’s stock, valued at $3,745,969.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Brett A. Pletcher sold 5,816 shares of the business’s stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $68.75, for a total transaction of $399,850.00. Following the sale, the executive vice president now directly owns 27,198 shares in the company, valued at approximately $1,869,862.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,884 shares of company stock worth $1,054,459. Insiders own 0.20% of the company’s stock.

Gilead Sciences stock traded down $0.90 during midday trading on Tuesday, hitting $66.98. 1,290,706 shares of the company’s stock were exchanged, compared to its average volume of 5,225,046. The stock has a market cap of $85.83 billion, a PE ratio of 10.89, a price-to-earnings-growth ratio of 4.05 and a beta of 1.12. The business has a 50 day moving average price of $67.26. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.53 and a current ratio of 3.62. Gilead Sciences, Inc. has a 12-month low of $60.32 and a 12-month high of $79.61.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.53 by $0.23. The business had revenue of $5.28 billion for the quarter, compared to the consensus estimate of $5.29 billion. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.48 earnings per share. Research analysts anticipate that Gilead Sciences, Inc. will post 6.62 earnings per share for the current fiscal year.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

See Also: Stock Symbols Definition, Examples, Lookup

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.